Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer
Open Access
- 7 April 2022
- journal article
- research article
- Published by Springer Nature in npj Breast Cancer
- Vol. 8 (1) , 1-9
Abstract
Platinum derivatives are commonly used for the treatment of patients with metastatic triple-negative breast cancer (TNBC). However, resistance often develops, leading to treatment failure. This expansion cohort (part C2) of the previously reported phase 1b trial (NCT02157792) is based on the recommended phase 2 dose of the combination of the ataxia-telangiectasia and Rad3-related (ATR) inhibitor berzosertib and cisplatin observed in patients with advanced solid tumors, including TNBC. Forty-seven patients aged ≥18 years with advanced TNBC received cisplatin (75 mg/m2; day 1) and berzosertib (140 mg/m2; days 2 and 9), in 21-day cycles. Berzosertib was well tolerated, with a similar toxicity profile to that reported previously for this combination. The overall response rate (90% confidence interval) was 23.4% (13.7, 35.8). No relevant associations were observed between response and gene alterations. Further studies combining ATR inhibitors with platinum compounds may be warranted in highly selected patient populations.Keywords
Funding Information
- Merck KGaA (N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A)
- Vertex Pharmaceuticals (N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A)
This publication has 43 references indexed in Scilit:
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancerBritish Journal of Cancer, 2012
- Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumorsNature Structural & Molecular Biology, 2011
- Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell linesBritish Journal of Cancer, 2011
- A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutationsNature Structural & Molecular Biology, 2011
- Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATRNature Chemical Biology, 2011
- ATR mediates cisplatin resistance in a p53 genotype-specific mannerOncogene, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006
- A Confidence Interval for the Median Survival Time1982
- THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIALBiometrika, 1934